# ADHD: Evidence-Based Diagnosis and Multimodal Treatment

## Overview

Attention-deficit/hyperactivity disorder is one of the most common neurodevelopmental disorders of childhood, affecting 9 to 10% of children and persisting into adulthood in approximately 60% of cases. Family physicians diagnose and manage the majority of childhood ADHD, making proficiency in evidence-based diagnosis, pharmacotherapy, and behavioral interventions essential.

## Diagnosis

### DSM-5 Criteria

The DSM-5 requires 6 or more symptoms of inattention and/or 6 or more symptoms of hyperactivity-impulsivity (5 or more for individuals aged 17 and older). Symptoms must have been present for at least 6 months, must have been present before age 12, must occur in 2 or more settings (home, school, work), must interfere with functioning or development, and must not be better explained by another mental disorder.

### Inattention Symptoms

The nine inattention symptoms include failing to give close attention to details or making careless mistakes, difficulty sustaining attention in tasks or play, not seeming to listen when spoken to directly, not following through on instructions or finishing tasks, difficulty organizing tasks and activities, avoiding or disliking tasks requiring sustained mental effort, losing things necessary for tasks, being easily distracted by extraneous stimuli, and being forgetful in daily activities.

### Hyperactivity-Impulsivity Symptoms

The nine hyperactivity-impulsivity symptoms include fidgeting or squirming in the seat, leaving the seat when expected to remain seated, running or climbing in inappropriate situations, being unable to play quietly, being "on the go" or "driven by a motor," talking excessively, blurting out answers before questions are completed, difficulty waiting one's turn, and interrupting or intruding on others.

### Presentations (Formerly "Subtypes")

ADHD presentations include predominantly inattentive (6 or more inattention symptoms with fewer than 6 hyperactive-impulsive), predominantly hyperactive-impulsive (6 or more hyperactive-impulsive symptoms with fewer than 6 inattentive), and combined (6 or more of both types). The presentation may change over time. Severity is classified as mild (few symptoms beyond those required for diagnosis with minor functional impairment), moderate (symptoms between mild and severe), or severe (many symptoms beyond threshold with marked functional impairment in multiple settings).

## Evaluation Process

### Clinical Interview

The evaluation includes a detailed developmental, academic, behavioral, and family history. Symptoms should be assessed across settings including home, school, and extracurricular activities. Screening for comorbid conditions such as anxiety, depression, oppositional defiant disorder, learning disabilities, and sleep disorders is essential. Family history of ADHD, mood disorders, and substance use disorders should be documented.

### Rating Scales

The Vanderbilt Assessment Scales include parent and teacher forms that screen for ADHD and common comorbidities including ODD, conduct disorder, anxiety, and depression; they are recommended by the AAP. The Conners Rating Scales have parent, teacher, and self-report versions and are widely validated. The SNAP-IV is a brief, free tool covering 18 DSM items for ADHD symptoms. Information must be obtained from both parents and teachers, representing a minimum of 2 settings.

### Neuropsychological Testing

Neuropsychological testing is not required for diagnosis but is useful when a learning disability is suspected, when the diagnosis is unclear, or when treatment response is poor. It evaluates cognitive abilities, executive function, processing speed, and academic achievement.

### What Is NOT Required

Routine EEG, brain imaging, blood tests, and genetic testing are not required for ADHD diagnosis. Continuous performance tests alone are insufficient for diagnosis. These tests may be indicated when the differential diagnosis includes seizure disorders, thyroid disease, or other medical conditions.

## Differential Diagnosis

The differential diagnosis includes anxiety disorders (difficulty concentrating from worry), depression (poor concentration and psychomotor agitation), learning disabilities (frustration and inattention limited to academic settings), sleep disorders (sleep-deprived children can appear hyperactive), trauma and PTSD (hypervigilance mimicking hyperactivity), autism spectrum disorder (which may coexist with ADHD), hearing or vision impairment, oppositional defiant disorder (which may coexist), substance use in adolescents, and gifted children with boredom (who are typically high performers when engaged).

## Treatment

### AAP Guidelines by Age

#### Preschool (4-5 Years)

Behavioral therapy, specifically parent training in behavior management, is first-line for preschool-age children. Methylphenidate may be prescribed if behavioral therapy does not provide significant improvement and symptoms are moderate to severe. Evidence for stimulants is more limited in this age group, and treatment should start at the lowest dose.

#### School-Age (6-11 Years)

First-line treatment includes FDA-approved stimulant medication and/or behavioral therapy. The combination of both is most effective, as demonstrated by the MTA study. Medication alone is more effective than behavioral therapy alone for core ADHD symptoms.

#### Adolescents (12-18 Years)

FDA-approved medication with assent from the adolescent is first-line, with behavioral therapy as an adjunct. Management should address organizational skills, academic support, and driving safety. Screening for substance use should occur before and during treatment.

### Stimulant Medications

#### Methylphenidate-Based

Short-acting methylphenidate IR (Ritalin) has a 3 to 4 hour duration requiring 2 to 3 daily doses. Intermediate-acting formulations such as Ritalin LA and Metadate CD last 6 to 8 hours. Long-acting methylphenidate OROS (Concerta) lasts 10 to 12 hours and cannot be crushed. Other formulations include Quillivant XR (liquid), Daytrana (patch), and Jornay PM (evening dosing for morning effect).

#### Amphetamine-Based

Short-acting mixed amphetamine salts IR (Adderall) last 4 to 6 hours. Long-acting options include mixed amphetamine salts XR (Adderall XR) lasting 10 to 12 hours and lisdexamfetamine (Vyvanse) lasting 10 to 14 hours. Lisdexamfetamine is a prodrug with lower abuse potential. Dextroamphetamine (Dexedrine) is another option.

| Medication | Class | Duration | Formulation Notes |
|------------|-------|----------|-------------------|
| Methylphenidate IR (Ritalin) | Methylphenidate | 3-4 hrs | 2-3 doses/day |
| Methylphenidate OROS (Concerta) | Methylphenidate | 10-12 hrs | Cannot crush; ascending release |
| Ritalin LA / Metadate CD | Methylphenidate | 6-8 hrs | Intermediate-acting |
| Daytrana (patch) | Methylphenidate | 9-10 hrs | Transdermal; flexible wear time |
| Mixed amphetamine salts IR (Adderall) | Amphetamine | 4-6 hrs | Short-acting |
| Mixed amphetamine salts XR (Adderall XR) | Amphetamine | 10-12 hrs | Once daily |
| Lisdexamfetamine (Vyvanse) | Amphetamine (prodrug) | 10-14 hrs | Lower abuse potential |

#### Prescribing Principles

Treatment should start low and titrate slowly every 1 to 2 weeks. Approximate target doses are methylphenidate at 1 mg/kg/day and amphetamine at 0.5 mg/kg/day. If the first stimulant class fails, the other class should be tried before moving to non-stimulants. The response rate is approximately 70% to the first stimulant, with 85 to 90% responding to one of the two classes. Long-acting formulations are preferred for school-age children because they simplify dosing, reduce stigma, and provide a more consistent effect.

#### Common Side Effects

The most common side effects include appetite suppression and weight loss, insomnia (which may be addressed by dose timing adjustment and sleep hygiene), headache, stomachache, and emotional lability or irritability from rebound effects. Growth suppression should be monitored and is typically a small effect of 1 to 2 cm over the first 2 years, with growth velocity usually normalizing thereafter.

#### Monitoring

Follow-up should occur within 1 month of initiation and then every 3 to 6 months. Height, weight, and BMI should be plotted on a growth chart at every visit. Heart rate and blood pressure should be checked at every visit. Efficacy should be assessed using follow-up rating scales such as the Vanderbilt follow-up form. Side effects should be screened for at each visit. Routine ECG is not recommended before starting stimulants unless there is a cardiac history or symptoms. Drug holidays during summer may be considered, though the evidence is mixed and should be discussed with the family.

### Non-Stimulant Medications

Atomoxetine (Strattera) is a selective norepinephrine reuptake inhibitor that is FDA-approved for ADHD, takes 4 to 6 weeks for full effect, has no abuse potential, and carries a black box warning for suicidal ideation. Among alpha-2 agonists, guanfacine ER (Intuniv) is FDA-approved for ADHD in ages 6 to 17 and is helpful for hyperactivity and impulsivity, with side effects including sedation, hypotension, and bradycardia. Clonidine ER (Kapvay) is FDA-approved for the same age range with similar properties but is more sedating. Both can be used as monotherapy or as adjuncts to stimulants. Viloxazine (Qelbree) is a selective norepinephrine reuptake inhibitor FDA-approved for ADHD in ages 6 and above and represents a relatively newer option.

### Behavioral Therapy

Parent training in behavior management teaches consistent consequences, positive reinforcement, and structured routines and is first-line for ages 4 to 5. Behavioral classroom interventions include daily report cards, token economies, and teacher-mediated strategies. Organizational skills training is appropriate for older children and adolescents. CBT is useful for comorbid anxiety and executive function challenges. Social skills training has mixed evidence when used alone but may benefit as part of a comprehensive program.

## Comorbidities

Anxiety, present in 30 to 40% of children with ADHD, may improve with ADHD treatment, with an SSRI and CBT considered for persistent symptoms. Depression occurs in 15 to 20% and requires regular screening with treatment of both conditions. ODD and conduct disorder are present in 40 to 60% and require parent training as an essential component with possible additional behavioral interventions. Learning disabilities are found in 20 to 30% and require neuropsychological testing and an IEP or 504 plan; ADHD medication does not treat learning disabilities. Sleep disorders affect 25 to 50% and warrant evaluation for primary sleep disorders, sleep hygiene counseling, and consideration of melatonin for sleep onset, with attention to medication timing. Tic disorders may coexist, and stimulants may be used cautiously, as tics may worsen, remain the same, or improve; alpha-2 agonists are helpful when tics are prominent. Autism spectrum disorder is now recognized as a coexisting diagnosis in DSM-5, requiring adjustment of behavioral strategies.

## Academic Accommodations

A 504 Plan provides classroom accommodations such as preferential seating, extra time on tests, and reduced homework. An IEP (Individualized Education Plan) is for children who also meet special education criteria, often due to comorbid learning disabilities. The family physician can support these efforts by documenting the diagnosis and functional impairment.

## ADHD in Adolescents: Special Considerations

Driving risks should be discussed, as adolescents with ADHD have higher accident rates, and medication improves driving performance. Substance use screening is important because ADHD is a risk factor for substance use disorder, though treatment does not increase this risk. Medication diversion awareness is relevant, with lisdexamfetamine having lower misuse potential due to its prodrug formulation. Transition planning to adult care should begin. Adolescents should be involved in treatment decisions to enhance autonomy and adherence.

<image>The AAP ADHD evaluation and treatment algorithm showing the diagnostic process (clinical interview, parent and teacher rating scales, rule out differential diagnoses), age-stratified first-line treatment recommendations (behavioral therapy first for ages 4-5, medication and/or behavioral therapy for ages 6-18), and the medication trial sequence (stimulant class 1, stimulant class 2, non-stimulant) with monitoring checkpoints.</image>

<image>A comparison chart of ADHD medications organized by class (methylphenidate vs. amphetamine vs. non-stimulant), formulation (short-acting, intermediate, long-acting), duration of action, typical starting and target doses for children, key side effects, and special considerations including abuse potential and formulation characteristics (capsule can be opened, liquid available, patch).</image>

<image>A visual summary of ADHD comorbidities showing the prevalence of coexisting conditions (anxiety 30-40%, ODD/CD 40-60%, learning disabilities 20-30%, depression 15-20%, sleep disorders 25-50%, tic disorders 10-20%) with brief management notes for each, emphasizing the need for comprehensive assessment beyond core ADHD symptoms.</image>

## Clinical Pearls

ADHD is a clinical diagnosis based on history and behavioral assessment; there is no single blood test, brain scan, or psychological test that diagnoses ADHD. Input must always be obtained from at least two settings using parent and teacher rating scales, and the diagnosis should not be made based on a single informant. If the first stimulant class does not work, the other class should be tried before concluding that stimulants have failed, as approximately 85 to 90% of children respond to one of the two stimulant classes. Behavioral therapy is first-line for preschool-age children aged 4 to 5, and medication should be started only if behavioral therapy is insufficient. Growth should be monitored at every visit; appetite suppression is the most common side effect but rarely requires discontinuation, and strategies include eating breakfast before medication takes effect and providing calorie-dense evening snacks. Routine ECG before starting stimulants is not recommended unless there is a personal history of cardiac disease, syncope, or family history of sudden cardiac death. Stimulant treatment does not increase the risk of future substance use disorder and in fact appears to be protective. Lisdexamfetamine is a prodrug that must be enzymatically converted to active dextroamphetamine, giving it lower misuse potential and more consistent duration of action.

## References

- Wolraich ML et al. Clinical Practice Guideline for ADHD: AAP. Pediatrics. 2019
- MTA Cooperative Group. 14-Month Randomized Clinical Trial of Treatment Strategies for ADHD. Arch Gen Psychiatry. 1999
- Pliszka SR. AACAP Practice Parameter for ADHD. J Am Acad Child Adolesc Psychiatry. 2007
- Cortese S et al. Comparative Efficacy and Tolerability of ADHD Medications. Lancet Psychiatry. 2018
- Faraone SV et al. The World Federation of ADHD International Consensus Statement. Neurosci Biobehav Rev. 2021